Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ESBA105 · 1 trial · 1 indication
An electronic Visual Analog Scale (eVAS) was used by the subject to assess ocular discomfort, both frequency and severity, at Day 0 (pre-treatment) and daily thereafter for 28 days. Assessments were entered into a LogPad® (handheld electronic device). The VAS frequency score ranged from 0 (rarely) to 100 (all the time), and the VAS severity score ranged from 0 (very mildly uncomfortable) to 100 (very severely uncomfortable). The Global Ocular Discomfort Score is a composite of the frequency and severity VAS scores (0-100).
| Arm | Type | Description |
|---|---|---|
| ESBA105 | EXPERIMENTAL | ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks |
| Vehicle | PLACEBO_COMPARATOR | ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks |
| Name | Type | Description |
|---|---|---|
| ESBA105 ophthalmic solution | BIOLOGICAL | - |
| ESBA105 vehicle | OTHER | Inactive ingredients used as Run-In and placebo comparator |
Inclusion Criteria: * Ongoing physician diagnosis of dry eye for at least 6 months. * Use of artificial tears, gels, lubricants, or re-wetting drops on a regular basis. * Experience persistent ocular discomfort. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Contact ...
Top 20 of 25 competitors
ESBA105 is an investigational monoclonal antibody being developed for chronic dry eye, a condition of the eyes. It is administered to patients with severe dry eye. The drug is currently in clinical development and has not been approved by the FDA.
ESBA105 is a monoclonal antibody, but its specific molecular target has not been disclosed. It is being studied for its potential to treat chronic dry eye, a condition characterized by insufficient tear production or excessive tear evaporation.
ESBA105 is being developed by Alcon Inc., a company traded under the ticker symbol ALC. Alcon is a global medical device company specializing in eye care products, and it is advancing ESBA105 through clinical trials for chronic dry eye.
ESBA105 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study involving 334 patients with severe dry eye. The drug remains investigational and is not yet approved.
ESBA105 has been studied in one clinical trial, identified as NCT01338610. This Phase 2 trial, titled 'ESBA105 in Patients With Severe Dry Eye,' was completed in the United States. It enrolled 334 participants aged 18 years and older, with no healthy volunteers included.
ESBA105 is a distinct investigational monoclonal antibody developed by Alcon Inc. for chronic dry eye. No alternative names for this drug have been reported, and it is not known to be identical to any other approved or investigational medication.